Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Use of antiretrovirals in newborns

David R. Burdge, Deborah M. Money, John C. Forbes, Lindy M. Samson and Sharon L. Walmsley
CMAJ October 28, 2003 169 (9) 901-902;
David R. Burdge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah M. Money
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John C. Forbes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindy M. Samson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon L. Walmsley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Joan Robinson is correct in pointing out the discrepancy between the Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive women and their offspring1 and the CDC guidelines for prophylaxis after needle-stick exposure.2 However, the issue of how best to manage infants born to HIV-positive women who probably have incompletely suppressed plasma viral load at term requires further study. We attempted to develop evidence-based guidelines, and currently there are good data supporting the use of zidovudine and nevirapine in the infant; hence our recommendation. Other approaches, such as the use of more extensive combination therapies in the infant, may eventually prove helpful in specific high-risk situations, but at present, in our opinion, there is insufficient safety or efficacy data to warrant such a recommendation.

It is noteworthy that the CDC guidelines for the management of occupational exposure2 are based largely on expert opinion, with very limited supporting data. It is also noteworthy that, with respect to this issue, the US Public Health Service Task Force guidelines for prevention of perinatal HIV transmission3 are identical with the Canadian consensus guidelines.1 With the currently recommended approach, vertical transmission of HIV has been reduced from about 25% to less than 1%.4 Although it would clearly be desirable to improve further on these results, we believe that an evidence-based approach is imperative in any such efforts, especially given the increasing concerns about the safety of these medications.

More research is needed into the precise role of and optimal approach to the infant component of perinatal prophylaxis for HIV infection. However, until more data become available, we remain comfortable with the current recommendations.

David R. Burdge Deborah M. Money John C. Forbes Oak Tree Clinic Children's and Women's Health Centre of British Columbia University of British Columbia Vancouver, BC Lindy M. Samson Division of Infectious Diseases Department of Pediatrics Children's Hospital of Eastern Ontario Ottawa, Ont. Sharon L. Walmsley Division of Infectious Diseases Department of Medicine Toronto Hospital University Health Network Toronto, Ont. On behalf of the Canadian HIV Trials Network Working Group on Vertical HIV Transmission

Footnotes

  • Competing interests: David Burdge, Deborah Money, John Forbes and Sharon Walmsley have all received speaker fees and/or educational grants from various pharmaceutical companies manufacturing drugs mentioned in the original article. Burdge, Forbes and Walmsley have received travel assistance from various pharmaceutical companies to attend meetings within the past 2 years. No competing interests were declared for Lindy Samson.

References

  1. 1.
    Burdge DR, Money DM, Forbes JC, Walmsley SL, Smaill FM, Boucher M, et al, on behalf of the Canadian HIV Trials Network Working Group on Vertical HIV Transmission. Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring [online appendix]. CMAJ 2003; 168 (13):Online-1 to Online-14. Available: www.cmaj.ca/cgi/data/168/13/1671/DC1/1 (accessed 2003 Aug 28).
  2. 2.
    US Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV and HIV and rationale for postexposure prophylaxis. MMWR Morbid Mortal Wkly Rep 2001;50(RR-11):1-42.
  3. 3.
    Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Bethesda (MD): US Department of Health and Human Services; 2003 Jun 16. Available: aidsinfo.nih.gov/guidelines/perinatal/archive/PER_061603.pdf (accessed 2003 Oct 2).
  4. 4.
    Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29(5):484-94.

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire